News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
KIMS already have a multi-specialty hospital and gastro unit at Vizag
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
ABDM Microsites Mobile Application for field officers and ABDM Microsites Dashboard launched for effective on-ground implementation and monitoring
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
